On Thursday, Shares of QUALCOMM, Inc (NASDAQ:QCOM), gain 1.86% to $55.33.
QUALCOMM, Inc, declared that its partner, Qualcomm Technologies, Inc., has introduced Qualcomm® Snapdragon Flight™, a highly optimized 58x40mm board targeted specifically for consumer drones and robotics applications. Qualcomm Snapdragon Flight is based on a Qualcomm® Snapdragon™ 801 processor, together with robust connectivity, advanced drone software and development tools, bringing cutting-edge mobile technologies to create a new class of consumer drones.
“Recently, drones are made from multiple component vendors providing separate solutions for photography, navigation and communications, adding to the cost and bulk of consumer drones,” said Raj Talluri, senior vice president, product administration, Qualcomm Technologies, Inc. “The Qualcomm Snapdragon Flight brings together the technologies that have defined the mobile industry onto a single board, enabling OEMs to build drones that are lighter, smaller, easy to use and affordable with long battery life and superior functionalities.”
Qualcomm Technologies also declared that Yuneec, a leading developer of consumer and professional drones with a long history of innovation in electric aviation, will be one of the first companies to embrace the Snapdragon Flight. Yuneec plans to release a drone based on the platform in 2016.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States. The company operates through three segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Planned Initiatives (QSI).
Shares of Sangamo Biosciences, Inc (NASDAQ:SGMO), inclined 21.71% to $7.96, during its last trading session.
Sangamo Biosciences, Inc, declared unanimous approval by the National Institutes of Health’s Recombinant DNA Advisory Committee (RAC) of a Phase 1 study protocol for a ZFP Therapeutic as a potential curative therapy for hemophilia B. The Factor IX program will be the first clinical study of in vivo genome editing and the first therapeutic application of Sangamo’s In Vivo Protein Replacement Platform (IVPRP).
Sangamo anticipates to file an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) by the end of 2015 and, pending FDA clearance, plans to initiate a Phase 1 clinical trial in 2016. The Company recently reattained all of its hemophilia assets from Shire plc as a result of the amendment to the companies’ 2012 partnership and license agreement.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs.
Finally, United Technologies Corporation (NYSE:UTX), ended its last trade with -0.39% loss, and closed at $91.49.
A webcast of United Technologies Corp. (UTX) President and CEO Gregory Hayes speaking at the Morgan Stanley 3rd Annual Laguna Conference is planned for 8:45 a.m. PT (11:45 a.m. ET) on Thursday, Sept. 17, 2015. The presentation will be broadcast live on the Internet at www.utc.com and will be archived on the website.
United Technologies Corporation provides technology products and services to building systems and aerospace industries worldwide. Its Otis segment designs, manufactures, sells, and installs passenger and freight elevators, escalators, and moving walkways; modernization products to upgrade elevators and escalators; and maintenance and repair services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
